Palvella Therapeutics(PVLA)
WAYNE, PABiotechnology
Focus: Palvella Therapeutics is a publicly-traded, small-molecule focused biotech developing treatments for rare dermatologic and genetic disorders. The company operates with a lean R&D budget and is advancing dual lead programs (PTX-022 and QTORIN) across multiple rare disease indications.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Palvella Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Palvella Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
QTORIN 3.9% rapamycin anhydrous gel
Cutaneous Venous MalformationsClinical Trials (1)
NCT06653842A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Phase 2Help build intelligence for Palvella Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.